B+
Bull case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
ERAS
ErascaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+8.0
Score
AI commentary
Headline tone turned sharply negative after the April 27, 2026 filing, with April 28 coverage emphasizing the patient death and large sell-off rather than the response-rate data. Primary sources support both the efficacy signal and the safety issue, but low coverage, unavailable fresh analyst revisions, and a negative deterministic prior argue for a cautious monitoring stance instead of treating the drop as a clear dislocation buy.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystPost-data safety digestion can keep ERAS-0015 under pressureHigh impact
The April 27, 2026 8-K paired strong preliminary response data with a Grade 3 pneumonitis case that progressed to Grade 5 after withdrawal of supportive care, which can continue to dominate near-term investor framing despite otherwise favorable early activity and tolerability metrics [#8-K-2026-04-27].
2026-12-31catalystERAS-4001 initial Phase 1 monotherapy data remains the next cleaner pipeline readoutHigh impact
The company said preliminary Phase 1 monotherapy data from BOREALIS-1 for pan-KRAS inhibitor ERAS-4001 is expected in the second half of 2026, giving investors a separate efficacy readout not tied to the April ERAS-0015 safety debate [#8-K-2026-04-27].
2027-06-30catalystERAS-0015 expansion and combination data are now the bigger proof pointHigh impact
Erasca said it initiated ERAS-0015 monotherapy expansion and combination dose-escalation cohorts ahead of prior guidance, with monotherapy expansion data and combination dose-escalation data expected in the first half of 2027; stronger durability and combination evidence would be needed to overcome cross-trial-comparison skepticism [#8-K-2026-04-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology